Sarcosine – Forschung

Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Marchi M, Galli G, Magarini FM, Mattei G, Galeazzi GM · Expert Opin Drug Metab Toxicol (2021)

Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.

Chang CH, Lin CH, Liu CY, Chen SJ, Lane HY · J Psychopharmacol (2020)

BDNF serum levels in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study).

Strzelecki D, Kałużyńska O, Wysokiński A · Psychiatry Res (2016)

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.

Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH · Biol Psychiatry (2008)

Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia.

Strzelecki D, Podgórski M, Kałużyńska O, Gawlik-Kotelnicka O, Stefańczyk L, Kotlicka-Antczak M · Nutrients (2015)

Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.

Tsai CH, Huang HC, Liu BL, Li CI, Lu MK, Chen X · Psychiatry Clin Neurosci (2014)

Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.

Strzelecki D, Podgórski M, Kałużyńska O, Gawlik-Kotelnicka O, Stefańczyk L, Kotlicka-Antczak M · Neurosci Lett (2015)

Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children.

Tzang RF, Chang YC, Tsai GE, Lane HY · J Psychopharmacol (2016)

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE · Arch Gen Psychiatry (2005)

Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression.

Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P · Biol Psychiatry (2013)

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.

Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY · Biol Psychiatry (2006)

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.

Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE · Int J Neuropsychopharmacol (2010)

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.

Tsai G, Lane HY, Yang P, Chong MY, Lange N · Biol Psychiatry (2004)

Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study).

Strzelecki D, Urban-Kowalczyk M, Wysokiński A · Psychiatry Res (2018)

No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia.

Strzelecki D, Kałużyńska O, Szyburska J, Wlazło A, Wysokiński A · Psychiatry Res (2015)

Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.

Strzelecki D, Podgórski M, Kałużyńska O, Stefańczyk L, Kotlicka-Antczak M, Gmitrowicz A · Int J Mol Sci (2015)

MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).

Strzelecki D, Kałużyńska O, Szyburska J, Wysokiński A · Int J Mol Sci (2016)

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.

Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH · World J Biol Psychiatry (2017)

Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the PULSAR study).

Strzelecki D, Urban-Kowalczyk M, Wysokiński A · Hum Psychopharmacol (2018)

Pharmacological and Mechanistic Interventions for Cognitive Impairment Associated With Schizophrenia: A Review of Registered Clinical Trials

Einfach gesagt: Despite extensive attempts to address CIAS, it remains an undertreated domain, and future trials should explore better ways to treat this important condition.

Peyrovian B, Palaniyappan L, Kolivakis TT, Margolese HC. · Acta psychiatrica Scandinavica (2026)